Review article: The role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 6, 2013, Pages 573-583

  Luttikhold, J ^a   De Ruijter, F M ^a   Van Norren, K ^b,c   Diamant, M ^a   Witkamp, R F ^c   Van Leeuwen, P A M ^a   Vermeulen, M A R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DANONE RESEARCH   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMCINAL; AZITHROMYCIN; CHOLECYSTOKININ; DOMPERIDONE; ERYTHROMYCIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GASTROINTESTINAL HORMONE; GHRELIN; GHRELIN RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; HORMONE RECEPTOR STIMULATING AGENT; METOCLOPRAMIDE; MOTILIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PRUCALOPRIDE; SECRETIN; SOMATOSTATIN; TZP 102; ULIMORELIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CRITICALLY ILL PATIENT; DELAYED GASTRIC EMPTYING; DRUG EFFICACY; DRUG MEGADOSE; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HORMONE ACTION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STOMACH EMPTYING; STOMACH FUNCTION DISORDER; STOMACH PARESIS; TREATMENT OUTCOME;

EID: 84883049448     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12421     Document Type: Article

References (120)

1. Weimann A, Braga M, Harsanyi L, et al,. ESPEN Guidelines on Enteral Nutrition: surgery including organ transplantation. Clin Nutr 2006; 25: 224-44.
2. Fruhwald S, Kainz J,. Effect of ICU interventions on gastrointestinal motility. Curr Opin Crit Care 2010; 16: 159-64.
3. Doig GS, Heighes PT, Simpson F, et al,. Early enteral nutrition, provided within 24 h of injury or intensive care unit admission, significantly reduces mortality in critically ill patients: a meta-analysis of randomised controlled trials. Intensive Care Med 2009; 35: 2018-27.
4. Gianotti L, Nelson JL, Alexander JW, et al,. Post injury hypermetabolic response and magnitude of translocation: prevention by early enteral nutrition. Nutrition 1994; 10: 225-31.
5. Fraser RJ, Bryant L,. Current and future therapeutic prokinetic therapy to improve enteral feed intolerance in the ICU patient. Nutr Clin Pract 2010; 25: 26-31.
6. Camilleri M,. Treatment of delayed gastric emptying. Available at: www.uptodate.com. Accessed September 1, 2012.
7. Nguyen NQ, Chapman M, Fraser RJ, et al,. Prokinetic therapy for feed intolerance in critical illness: one drug or two? Crit Care Med 2007; 35: 2561-7.
8. Tolessa T, Gutniak M, Holst JJ, et al,. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998; 43: 2284-90.
9. Jones KL, Berry M, Kong MF, et al,. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999; 22: 339-44.
10. Kaji M, Nomura M, Tamura Y, Ito S,. Relationships between insulin resistance, blood glucose levels and gastric motility: an electrogastrography and external ultrasonography study. J Med Invest 2007; 54: 168-76.
11. Nguyen NQ, Fraser RJ, Bryant LK, et al,. Diminished functional association between proximal and distal gastric motility in critically ill patients. Intensive Care Med 2008; 34: 1246-55.
12. Chapman M, Fraser R, Vozzo R, et al,. Antro-pyloro-duodenal motor responses to gastric and duodenal nutrient in critically ill patients. Gut 2005; 54: 1384-90.
13. Artinian V, Krayem H, DiGiovine B,. Effects of early enteral feeding on the outcome of critically ill mechanically ventilated medical patients. Chest 2006; 129: 960-7.
14. Usellini L, Buchan AM, Polak JM, et al,. Ultrastructural localization of motilin in endocrine cells of human and dog intestine by the immunogold technique. Histochemistry 1984; 81: 363-8.
15. Poitras P, Peeters TL,. Motilin. Curr Opin Endocrinol Diabetes Obes 2008; 15: 54-7.
16. Burt M, Scott A, Williard WC, et al,. Erythromycin stimulates gastric emptying after esophagectomy with gastric replacement: a randomized clinical trial. J Thorac Cardiovasc Surg 1996; 111: 649-54.
17. Chapman MJ, Fraser RJ, Kluger MT, et al,. Erythromycin improves gastric emptying in critically ill patients intolerant of nasogastric feeding. Crit Care Med 2000; 28: 2334-7.
18. Janssens J, Peeters TL, Vantrappen G, et al,. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 1028-31.
19. Ritz MA, Chapman MJ, Fraser RJ, et al,. Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill. Intensive Care Med 2005; 31: 949-54.
20. Dhir R, Richter JE,. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J Clin Gastroenterol 2004; 38: 237-42.
21. Lamian V, Rich A, Ma Z, et al,. Characterization of agonist-induced motilin receptor trafficking and its implications for tachyphylaxis. Mol Pharmacol 2006; 69: 109-18.
22. Kannan S,. Molecular basis of the evolution of drug resistance: potential role of the transient state during infection/drug treatment. Med Hypotheses 2004; 63: 71-2.
23. Hawkyard CV, Koerner RJ,. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother 2007; 59: 347-58.
24. Leming S, Broad J, Cozens SJ, et al,. GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011; 23: 958-e410.
25. Li JJ, Chao HG, Wang H, et al,. Discovery of a potent and novel motilin agonist. J Med Chem 2004; 47: 1704-8.
26. Talley NJ, Verlinden M, Snape W, et al,. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 1653-61.
27. Talley NJ, Verlinden M, Geenen DJ, et al,. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001; 49: 395-401.
28. McCallum RW, Cynshi O,. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007; 26: 107-16.
29. Kojima M, Hosoda H, Date Y, et al,. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
30. Cummings DE, Purnell JQ, Frayo RS, et al,. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-9.
31. Crona D, MacLaren R,. Gastrointestinal hormone concentrations associated with gastric feeding in critically ill patients. JPEN J Parenter Enteral Nutr 2012; 36: 189-96.
32. Tack J, Depoortere I, Bisschops R, et al,. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22: 847-53.
33. Murray CD, Martin NM, Patterson M, et al,. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005; 54: 1693-8.
34. Levin F, Edholm T, Schmidt PT, et al,. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 2006; 91: 3296-302.
35. Bisschops R,. Ligand and electrically induced activation patterns in myenteric neuronal networks. Confocal calcium imaging as a bridge between basic and human physiology. Verh K Acad Geneeskd Belg 2008; 70: 105-45.
36. Binn M, Albert C, Gougeon A, et al,. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides 2006; 27: 1603-6.
37. Ejskjaer K, Wo JM, Esfandyari T, et al,. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013; 25: 140-50.
38. Ejskjaer N, Dimcevski G, Wo J, et al,. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 2010; 22: 1069-e281.
39. Ejskjaer N, Vestergaard ET, Hellstrom PM, et al,. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29: 1179-87.
40. Pederson RA, Brown JC,. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 1976; 99: 780-5.
41. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C,. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005; 31: 233-42.
42. Schirra J, Katschinski M, Weidmann C, et al,. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103.
43. Edholm T, Degerblad M, Gryback P, et al,. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 2010; 22: 1191-200.
44. Bayliss WM, Starling EH,. The mechanism of pancreatic secretion. J Physiol 1902; 28: 325-53.
45. Cheng CY, Chu JY, Chow BK,. Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system. Neuropsychopharmacology 2011; 36: 459-71.
46. Chey WY, Hitanant S, Hendricks J, Lorber SH,. Effect of secretin and cholecystokinin on gastric emptying and gastric secretion in man. Gastroenterology 1970; 58: 820-7.
47. Jin HO, Lee KY, Chang TM, et al,. Secretin: a physiological regulator of gastric emptying and acid output in dogs. Am J Physiol 1994; 267 (4 Pt 1): G702-8.
48. Phaosawasdi K, Fisher RS,. Hormonal effects on the pylorus. Am J Physiol 1982; 243: G330-5.
49. Okike N, Kelly KA,. Vagotomy impairs pentagastrin-induced relaxation of canine gastric fundus. Am J Physiol 1977; 232: E504-9.
50. Mearadji B, Straathof JW, Lamers CB, Masclee AA,. Effect of gastrin on proximal gastric motor function in humans. Neurogastroenterol Motil 1999; 11: 449-55.
51. He MR, Song YG, Zhi FC,. Gastrointestinal hormone abnormalities and G and D cells in functional dyspepsia patients with gastric dysmotility. World J Gastroenterol 2005; 11: 443-6.
52. Ivy AC, Oldberg EA,. A hormonal mechanism for gallbladder contraction and evacuation. Am J Physiol 1928; 86: 599-613.
53. Dockray GJ,. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 2012; 19: 8-12.
54. Sanger GJ, Lee K,. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat Rev Drug Discov 2008; 7: 241-54.
55. Chaudhri O, Small C, Bloom S,. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1187-209.
56. Moran TH, McHugh PR,. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 1982; 242: R491-7.
57. Wank SA,. Cholecystokinin receptors. Am J Physiol 1995; 269 (5 Pt 1): G628-46.
58. Borovicka J, Kreiss C, Asal K, et al,. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am J Physiol 1996; 271: G448-53.
59. Nguyen NQ, Fraser RJ, Chapman MJ, et al,. Feed intolerance in critical illness is associated with increased basal and nutrient-stimulated plasma cholecystokinin concentrations. Crit Care Med 2007; 35: 82-8.
60. Fried M, Erlacher U, Schwizer W, et al,. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991; 101: 503-11.
61. Little TJ, Gopinath A, Patel E, et al,. Gastric emptying of hexose sugars: role of osmolality, molecular structure and the CCK(1) receptor. Neurogastroenterol Motil 2010; 22: 1183-90.
62. Cremonini F, Camilleri M, McKinzie S, et al,. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005; 100: 652-63.
63. Reichlin S,. Somatostatin. N Engl J Med 1983; 309: 1495-501.
64. Kumar U, Grant M,. Somatostatin and somatostatin receptors. Results Probl Cell Differ 2009; 50: 137-84.
65. Reisine T, Bell GI,. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427-42.
66. Shimada M, Date Y, Mondal MS, et al,. Somatostatin suppresses ghrelin secretion from the rat stomach. Biochem Biophys Res Commun 2003; 302: 520-5.
67. Stengel A, Goebel-Stengel M, Wang L, et al,. Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2. Am J Physiol Gastrointest Liver Physiol 2011; 301: G239-48.
68. Stengel A, Goebel-Stengel M, Wang L, et al,. Central administration of pan-somatostatin agonist ODT8-SST prevents abdominal surgery-induced inhibition of circulating ghrelin, food intake and gastric emptying in rats. Neurogastroenterol Motil 2011; 23: 294-308.
69. Hurst RD, Modlin IM,. The therapeutic role of octreotide in the management of surgical disorders. Am J Surg 1991; 162: 499-507.
70. Schjoldager B, Mortensen PE, Myhre J, et al,. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34: 1411-9.
71. Dakin CL, Small CJ, Batterham RL, et al,. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-95.
72. Dakin CL, Small CJ, Park AJ, et al,. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002; 283: E1173-7.
73. Dubrasquet M, Bataille D, Gespach C,. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 1982; 2: 391-5.
74. Maida A, Lovshin JA, Baggio LL, Drucker DJ,. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008; 149: 5670-8.
75. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC,. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-71.
76. Schirra J, Nicolaus M, Woerle HJ, et al,. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009; 21: 609-18.
77. Wettergren A, Schjoldager B, Mortensen PE, et al,. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.
78. Wettergren A, Maina P, Boesby S, Holst JJ,. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Scand J Gastroenterol 1997; 32: 552-5.
79. Deane AM, Nguyen NQ, Stevens JE, et al,. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95: 215-21.
80. Little TJ, Pilichiewicz AN, Russo A, et al,. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91: 1916-23.
81. Nauck MA, Heimesaat MM, Behle K, et al,. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-46.
82. Deane AM, Chapman MJ, Fraser RJ, et al,. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009; 13: R67.
83. Drucker DJ, Erlich P, Asa SL, Brubaker PL,. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 7911-6.
84. Damholt AB, Buchan AM, Holst JJ, Kofod H,. Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2. Endocrinology 1999; 140: 4800-8.
85. Yusta B, Huang L, Munroe D, et al,. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 744-55.
86. Wojdemann M, Wettergren A, Hartmann B, et al,. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999; 84: 2513-7.
87. Bozkurt A, Naslund E, Holst JJ, Hellstrom PM,. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul Pept 2002; 107: 129-35.
88. Guan X, Stoll B, Lu X, et al,. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003; 125: 136-47.
89. Nagell CF, Wettergren A, Pedersen JF, et al,. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004; 39: 353-8.
90. Estall JL, Drucker DJ,. Glucagon-like Peptide-2. Annu Rev Nutr 2006; 26: 391-411.
91. Drucker DJ,. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005; 1: 22-31.
92. Jeppesen PB, Hartmann B, Thulesen J, et al,. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120: 806-15.
93. McTigue DM, Rogers RC,. Pancreatic polypeptide stimulates gastric acid secretion through a vagal mechanism in rats. Am J Physiol 1995; 269: R983-7.
94. Hazelwood RL,. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med 1993; 202: 44-63.
95. Batterham RL, Cohen MA, Ellis SM, et al,. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-8.
96. Katsuura G, Asakawa A, Inui A,. Roles of pancreatic polypeptide in regulation of food intake. Peptides 2002; 23: 323-9.
97. Okumura T, Pappas TN, Taylor IL,. Intracisternal injection of pancreatic polypeptide stimulates gastric emptying in rats. Neurosci Lett 1994; 178: 167-70.
98. Schmidt PT, Naslund E, Gryback P, et al,. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 2005; 90: 5241-6.
99. Tatemoto K,. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 1982; 79: 2514-8.
100. Broome M, Hokfelt T, Terenius L,. Peptide YY (PYY)-immunoreactive neurons in the lower brain stem and spinal cord of rat. Acta Physiol Scand 1985; 125: 349-52.
101. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al,. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-7.
102. Adrian TE, Savage AP, Sagor GR, et al,. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89: 494-9.
103. Korner J, Leibel RL,. To eat or not to eat-how the gut talks to the brain. N Engl J Med 2003; 349: 926-8.
104. Savage AP, Adrian TE, Carolan G, et al,. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166-70.
105. Nematy M, O'Flynn JE, Wandrag L, et al,. Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study. Crit Care 2006; 10: R10.
106. Nguyen NQ, Fraser RJ, Bryant LK, et al,. The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients. Crit Care 2007; 11: R132.
107. Soop M, Nygren J, Myrenfors P, et al,. Preoperative oral carbohydrate treatment attenuates immediate postoperative insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E576-83.
108. Maganti K, Onyemere K, Jones MP,. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98: 259-63.
109. Larson JM, Tavakkoli A, Drane WE, et al,. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 2010; 16: 407-13.
110. Moshiree B, McDonald R, Hou W, Toskes PP,. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010; 55: 675-83.
111. Tack J, van Outryve M, Beyens G, et al,. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-65.
112. Bouras EP, Camilleri M, Burton DD, McKinzie S,. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682-6.
113. McCallum RW, Valenzuela G, Polepalle S, Spyker D,. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 1991; 258: 136-42.
114. Rao AS, Camilleri M,. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31: 11-9.
115. Hyett B, Martinez FJ, Gill BM, et al,. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 2009; 137: 445-52.
116. Jung HK, Choung RS, Locke GR 3rd, et al,. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009; 136: 1225-33.
117. Sugumar A, Singh A, Pasricha PJ,. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008; 6: 726-33.
118. Patterson D, Abell T, Rothstein R, et al,. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 1230-4.
119. Silvers D, Kipnes M, Broadstone V, et al,. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998; 20: 438-53.
120. Drolet B, Rousseau G, Daleau P, et al,. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102: 1883-5.